Retatrutide, developed by Soma, represents a exciting breakthrough in body regulation. This dual-action drug combines GLP-1 receptor activity with gut-derived receptor agonist activation , demonstrating remarkable potential in patient data for metabolic improvement. Scientists believe Retatrutide